Yamashita Hiroshi, Nguyen Dan T, Chung Euiheon
Department of Medical System Engineering and School of Mechatronics, Gwangju Institute of Science and Technology, Gwangju, South Korea.
Methods Mol Biol. 2014;1098:145-51. doi: 10.1007/978-1-62703-718-1_12.
Only a few techniques are currently available for quantifying systemic metastases in preclinical models. Cancer cell expression of naturally secreted Gaussia luciferase (Gluc) provides a useful circulating biomarker that enables the monitoring of metastatic tumor burden and of treatment response from minimal drops of blood. This blood-based Gluc assay exhibits several distinct advantages: (1) It is highly sensitive in quantifying metastatic tumor growth, particularly when compared to whole-body bioluminescence imaging (BLI) alone; (2) It is quantitative by nature and reflects viable tumor burden in a minimally invasive manner; (3) Through longitudinal collection of blood samples, treatment response can be monitored in real-time; and (4) Gluc bioluminescence provides a means to localize and assess metastatic colonization using BLI. By elucidating the progression of systemic metastases and therapeutic response in animal models, the blood-based Gluc assay is emerging as a valuable quantitative tool for novel drug development.
目前在临床前模型中，仅有少数技术可用于定量全身转移。癌细胞表达自然分泌的高斯荧光素酶（Gluc）可提供一种有用的循环生物标志物，能够通过极少量血样监测转移性肿瘤负荷及治疗反应。这种基于血液的Gluc检测具有几个明显优势：（1）在定量转移性肿瘤生长方面高度灵敏，尤其是与单独的全身生物发光成像（BLI）相比；（2）本质上是定量的，以微创方式反映存活肿瘤负荷；（3）通过纵向采集血样，可实时监测治疗反应；（4）Gluc生物发光提供了一种利用BLI定位和评估转移性定植的方法。通过阐明动物模型中全身转移的进展和治疗反应，基于血液的Gluc检测正成为新型药物研发的一种有价值的定量工具。
